A recent study demonstrated that, in patients with heart failure (HF) and diabetes, dapagliflozin, a sodium-glucose cotransporter (SGLT2) inhibitor, provided beneficial effects related to the worsening of HF, hospitalizations and cardiovascular death, regardless of frailty class. Here, SLC5A2 is linked to diabetes mellitus.